Journey Medical Corporation Common Stock
DERMJourney Medical Corporation (DERM) is a dermatology-focused biopharmaceutical company that develops and commercializes dermatology products. The company focuses on acquiring, developing, and marketing prescription and over-the-counter dermatology treatments, aiming to address unmet needs in skin health and dermatological care.
Company News
Pomerantz LLP is investigating Journey Medical Corporation for potential securities fraud following the company's March 25, 2026 earnings report. Management disclosed that prescription demand for Emrosi exceeded reported revenue due to reimbursement timing and co-pay assistance program usage, with some scripts not being reimbursed. The stock fell...
The global tetracyclines market is experiencing steady growth at a CAGR of 5.23%, driven by broad-spectrum efficacy, cost-effectiveness, and expanding applications in respiratory infections, dermatology, and sexual health. Doxycycline dominates with 46.1% market share, while oral formulations lead with 64.0% share. Key growth drivers include risi...
EmergingGrowth.com announced the schedule for its 85th conference featuring presentations from multiple public companies across various sectors on August 20-21, 2025, providing insights into emerging growth companies.
Journey Medical Corporation announced that the FDA has approved Emrosi™, a new treatment for inflammatory lesions of rosacea in adults. The approval is supported by positive data from the company's Phase 3 clinical trials.
SCOTTSDALE, Ariz., May 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatmen...
